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Purpose/Objective: The use of biological information on 
tumour control and normal-tissue complications for 
treatment plan optimisation is a first step towards 
individualised radiotherapy. However, the robustness of the 
underlying models for tumour control probability (TCP) and 
normal-tissue complication probability (NTCP) needs to be 
analysed prior to any clinical application.  
Materials and Methods: This work investigates the robustness 
of the TCP and NCTP models implemented in the biological 
optimisation tool of EclipseTM for the case of prostate cancer. 
The CT images and structure sets of ten patients previously 
treated with helical tomotherapy were imported in Eclipse 
and several biologically-based IMRT plans were created for 
each patient (dose prescription: 72 Gy in 40 fractions). The 
plans were optimised by using the NTCP Lyman model for 
rectal bleeding and bladder contracture as objective and by 
putting physical constraints to the PTV so that the tumour 
coverage was comparable to that achieved with 
TomoTherapy®. The NTCP model parameters were then 
varied individually within the ranges found in the literature. 
Among others, the values of D50, n, and m were varied for the 
NTCP model, for both rectum and bladder. Finally, a VMAT 
plan was calculated for each patient. This plan was optimized 
in order to achieve tumour coverage and DVH goals 
comparable to those of the original tomotherapy plan.  
Results: The results of this plan comparison study show that 
the NTCP Lyman model implemented in Eclipse is robust with 
respect to variations of the parameters m and n (representing 
slope and dose-volume parameter, respectively), while 
changes of D50 (within 10 %) already resulted in significant 
DVH variations. The DVH goals for rectum and bladder 
remained within the limits recommended by the QUANTEC 
survey, although V50 for the rectum was systematically higher 
than in the tomotherapy and VMAT plans. Remarkably, for 
each patient, the dose hot spots for rectum and bladder were 
significantly reduced (down to 99-102 % of the prescribed 
dose) in all biologically-optimised plans. Moreover, it was 
observed that the optimisation time was lower than for the 
VMAT plan and that extra contouring for the organs at risk 
overlapping with the PTV was redundant. 
Conclusions: Biologically-based optimisation tools allow for 
individualised dose concepts and, in principle, could be 
safely used for treatment planning of prostate cancer. They 
have the advantage of reducing optimisation time, contouring 
process, and dose hot spots. However, the NTCP model 
parameters, especially D50, should be known with 
uncertainties lower than 10 % and the DVH goals carefully 
verified. Further studies for dose prescriptions up to 80 Gy 
are currently being carried out. 
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Purpose/Objective: Peptide receptor radionuclide therapy 
(PRRT) with 177Lu labelled DOTATATE is increasingly used in 
the treatment of neuroendocrine tumours (NET) and other 
tumours expressing type 2 somatostatin receptors. In PRRT 
the kidney is generally the dose-limiting organ because low 
molecular weight radionuclide conjugates are mainly 
excreted by the kidney, where a fraction is reabsorbed, 
leading to a high locally absorbed dose. The second critical 
organ in PRRT is bone marrow whose dosimetry is usually 
determined from the activity concentration in the blood. 
Dosimetry in radionuclide therapy is commonly based on the 
MIRD model at the organ level (although MIRD also provides a 
voxel level scheme) which is not based on specific patients 
anatomy and tracers kinetics data and which can not provide 
3D dose volumes. The aim of this work was to evaluate the 
feasibility of using a more accurate, patient specific, 3D dose 
calculation method in PRRT that could also take into account 
specific patient kinetic data. 
Materials and Methods: The eleven patients enrolled in this 
study were treated with 177Lu-labeled peptides for 
neuroendocrine tumours. The mean administered activity per 
cycle was 5.7 ± 1.2 GBq. All patients underwent a series of 
five sequential SPECT-CT scans at 1, 4, 24, 44, 72 h post-
injection to evaluate the bio-distribution of the compound as 
a function of time. The SPECT-CT scanner (Symbia T2, 
Siemens Medical, Germany) was calibrated for absolute 
quantification of 177Lu using reference phantom 
measurements. Sequential SPECT-CT scans were registered to 
the first CT scan position. A deformable image registration 
algorithm was used to register all the anatomical scans of the 
sequential CT in the same frame of reference. The activity 
distribution in each SPECT scan were modified accordingly, 
using the generated deformation maps. 3D dose calculations 
were carried out using the Raydose MC code which has been 
specifically designed for molecular radiotherapy. 
Conventional radiotherapy plan evaluation metrics such as 
Dose Volume Histograms (DVHs) were generated for the 
kidneys, both average and maximum dose were extracted 
from the 3D dose map and were compared with the mean 
organ level MIRD calculations carried out with the 
Olinda/EXM software. 
Results: The SPECT activity scans reported in counts per 
voxel were converted in activity concentration (BQML) using 
a calibration factor measured in standard conditions using a 
cylindrical phantom homogeneously filled with 177Lu. 
Raydose calculations were validated in these standard 
conditions within 5% of the expected nominal dose. Raydose 
patient dose calculations were carried out on a Dell 
PowerEdge R620 dual core Xeon E-26XX processor machine 
and took, on average, 30 minutes per scan per patient to 
complete with a statistical uncertainty of +/- 2% per voxel. 
Activity integration at the voxel level was carried out 
